Xention, a cardiovascular biotech company, specialised in the discovery and development of ion channel-modulating drugs.
Its assets have now been partnered with or acquired by pharmaceutical partners.
Copyright © 2024 Seroba. All rights reserved.
Legal | Privacy | Sustainability
Its assets have now been partnered with or acquired by pharmaceutical partners.
Copyright © 2024 Seroba. All rights reserved.
Legal | Privacy | Sustainability
Total raised: $12.6M
Investors 3
| Date | Name | Website |
| - | Seroba Lif... | seroba-lif... |
| - | Forbion | forbion.co... |
| - | Albion Cap... | albion.cap... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 25.11.2010 | Series D | $12.6M | - |
Mentions in press and media 1
| Date | Title | Description |
| 25.11.2010 | Xention Closes £8M Series D Financing | Xention, Ltd., a Cambridge, UK-based biopharmaceutical company specializing in the discovery and development of ion channel-modulating drugs, has closed an £8m series D financing. The round was led by new investor Seroba-Kernel Life Science... |